Corcept Therapeutics (CORT) News Today $55.31 +0.87 (+1.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Hennion & Walsh Asset Management Inc. Cuts Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Hennion & Walsh Asset Management Inc. cut its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 30.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,122 shares of the bJanuary 18 at 4:07 AM | marketbeat.comBurney Co. Raises Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Burney Co. boosted its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 9.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 473,821 shares of the biotechnology company's stock after purchasing an additional 39,657 shares dJanuary 15 at 9:55 AM | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $111,188.00 in StockCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.January 14, 2025 | marketbeat.comJPMorgan Chase & Co. Has $11.71 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)JPMorgan Chase & Co. boosted its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 43.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 253,070 shares of the biotechnology company'sJanuary 13, 2025 | marketbeat.comRange Financial Group LLC Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)Range Financial Group LLC acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,452 shares of the biotechnology cJanuary 7, 2025 | marketbeat.comCorcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased GuidanceJanuary 7, 2025 | msn.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $1,007,800.00 in StockJanuary 7, 2025 | insidertrades.comSean Maduck Sells 20,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) StockCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now directly owns 85,318 shares of the company's stock, valued at $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.January 6, 2025 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of "Buy" by BrokeragesCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) has received a consensus recommendation of "Buy" from the five research firms that are presently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month tarJanuary 1, 2025 | marketbeat.comCorcept Therapeutics Inc (CORT) Submits NDA for Relacorilant to FDADecember 31, 2024 | gurufocus.comCorcept Therapeutics Submits New Drug Application for Cushing's Sydrome TreatmentDecember 30, 2024 | marketwatch.comCorcept Therapeutics submits relacorilant new drug application to FDADecember 30, 2024 | markets.businessinsider.comCorcept Therapeutics Submits NDA For Relacorilant To Treat HypercortisolismDecember 30, 2024 | markets.businessinsider.comKuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law FirmDecember 30, 2024 | investing.comCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients With HypercortisolismDecember 30, 2024 | businesswire.comPrincipal Financial Group Inc. Has $22.94 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Principal Financial Group Inc. lessened its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 495,658 shares of the biotechnology company's stock after selling 20,770 shares duDecember 26, 2024 | marketbeat.comWill Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?December 24, 2024 | insidermonkey.comWhat is Zacks Research's Forecast for CORT FY2025 Earnings?Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at Zacks Research cut their FY2025 earnings per share estimates for Corcept Therapeutics in a report released on Wednesday, December 18th. Zacks Research analyst K. Das now expects that the biotechnology coDecember 23, 2024 | marketbeat.comZacks Research Has Negative Outlook for CORT Q1 EarningsCorcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Wednesday, December 18th. Zacks Research analyst K. Das now expects that the biotechnology company wilDecember 20, 2024 | marketbeat.comGeode Capital Management LLC Purchases 99,470 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Geode Capital Management LLC raised its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,378,758 shares of the biotechnolDecember 19, 2024 | marketbeat.comWorld Investment Advisors LLC Invests $503,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)World Investment Advisors LLC purchased a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,876 shares of the biotechnology company's stock, vaDecember 18, 2024 | marketbeat.comCorcept Therapeutics presents results from relacorilant studyDecember 17, 2024 | markets.businessinsider.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in NovemberCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 17,050,000 shares, a decrease of 7.0% from the November 15th total of 18,340,000 shares. Approximately 18.9% of the company's shares are sold short. Based on an average daily volume of 999,000 shares, the short-interest ratio is currently 17.1 days.December 16, 2024 | marketbeat.comCorcept's Relacorilant Shows Long-Term Cardiometabolic Benefits In Hypercortisolism PatientsDecember 16, 2024 | markets.businessinsider.comCorcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with HypercortisolismDecember 16, 2024 | finance.yahoo.comStifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Stifel Financial Corp increased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 30.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,967 shares of the biotechnology company's stock after aDecember 16, 2024 | marketbeat.comState Street Corp Acquires 19,893 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)State Street Corp boosted its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 0.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,519,263 shares of the biotechnology company's stock after purchDecember 14, 2024 | marketbeat.comCorcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control DiabetesDecember 13, 2024 | benzinga.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells 2,200 Shares of StockDecember 13, 2024 | insidertrades.comVerition Fund Management LLC Lowers Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Verition Fund Management LLC trimmed its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 76.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,758 shares of the biotechnology company's stock afterDecember 13, 2024 | marketbeat.comCorcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in StudyDecember 12, 2024 | marketwatch.comOptimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory AdvantagesDecember 12, 2024 | markets.businessinsider.comCorcept Therapeutics Inc (CORT) Announces Positive Results from CATALYST StudyDecember 12, 2024 | gurufocus.comCorcept Therapeutics says CATALYST trial met primary endpointDecember 12, 2024 | tipranks.comCorcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control DiabetesDecember 12, 2024 | businesswire.comCorcept Therapeutics Fall 3.5 After ALS Drug Fails TrialDecember 11, 2024 | marketwatch.comCorcept says DAZALS study did not meet primary endpointDecember 11, 2024 | markets.businessinsider.comCorcept Therapeutics Inc (CORT) Announces DAZALS Study Results for ALS TreatmentDecember 11, 2024 | gurufocus.comCorcept Therapeutics' ALS drug fails in mid-stage trialDecember 11, 2024 | reuters.comCorcept Therapeutics Incorporated Common Stock (CORT)December 11, 2024 | nasdaq.comCorcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)December 11, 2024 | businesswire.comExecutive Wealth Management LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Executive Wealth Management LLC acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 60,594 shares of the biotechnology company'sDecember 10, 2024 | marketbeat.comTanaka Capital Management Inc. Has $5.19 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Tanaka Capital Management Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 11.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 112,136 shares of the biotechnology company's stockDecember 9, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Two Sigma Advisers LPTwo Sigma Advisers LP decreased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 11.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 457,100 shares of the biotechnology companDecember 9, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 18,179 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 8.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. ThDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Sells 17,793 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Janus Henderson Group PLC trimmed its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 5.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 324,017 shares of the biotechnology company'sDecember 8, 2024 | marketbeat.comPositive Outlook for Corcept Therapeutics Amid Phase III Delays and Market Opportunities for RelacorilantDecember 7, 2024 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)December 7, 2024 | markets.businessinsider.comFmr LLC Has $63.12 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Fmr LLC increased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 24.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,363,922 shares of the biotechnology company's stDecember 7, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five yearsDecember 4, 2024 | finance.yahoo.com Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address CORT Media Mentions By Week CORT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CORT News Sentiment▼1.000.64▲Average Medical News Sentiment CORT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CORT Articles This Week▼56▲CORT Articles Average Week Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Royalty Pharma News Today Jazz Pharmaceuticals News Today Perrigo News Today Supernus Pharmaceuticals News Today Pacira BioSciences News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CORT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
